Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROact: Olaparib + Abiraterone in mHSPC with HRR Mutation
NCT05167175Phase 2Unknown
- Start
- Mar 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in prostate cancer (PCa). Status: unknown.
02
Drugs
olaparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05167175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05167175.